Trials that use: Covariate adjustment
4,539 results
- A Study of LY3006072 in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3006072 in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01640249).
- A Study of LY3041658 in Adults With Hidradenitis Suppurativa: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3041658 in Adults With Hidradenitis Suppurativa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04493502).
- A Study of LY3050258 in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3050258 in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02121834).
- A Study of LY3053102 in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3053102 in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01736241).
- A Study of LY3113593 in Participants With Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3113593 in Participants With Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02604160).
- A Study of LY3185643 and rGlucagon in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3185643 and rGlucagon in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02951780).
- A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer’s Disease: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of LY3463251 in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3463251 in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03764774).
- A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study of LY3832479 (LY-CoV016) in Healthy Participants 1: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3832479 (LY-CoV016) in Healthy Participants 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04611789).
- A Study of LY900014 Formulations in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY900014 Formulations in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02317575).
- A Study of LY900014 in Participants With Type 2 Diabetes Mellitus: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY900014 in Participants With Type 2 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin’s Lymphoma (NHL): Complete Statistical AnalysisIndependent statistical analysis of A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma: primary endpoint results, effect estimate with confidence…
- A Study of Management of Tarceva – Induced Rash in Patients With Non-Small Cell Lung Cancer.: Complete Statistical AnalysisIndependent statistical analysis of A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis: Complete Statistical AnalysisIndependent statistical analysis of A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.: Complete Statistical AnalysisIndependent statistical analysis of A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Study of Mirikizumab in Participants With Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of A Study of Mirikizumab in Participants With Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03718884).
- A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011): Complete Statistical AnalysisIndependent statistical analysis of A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.: Complete Statistical AnalysisIndependent statistical analysis of A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.: primary endpoint results, effect estimate with confidence interval,…
- A Study of MORAb-202 Versus Investigator’s Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: primary endpoint results, effect estimate…
- A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression: Complete Statistical AnalysisIndependent statistical analysis of A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults: Complete Statistical AnalysisIndependent statistical analysis of A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05415462).
- A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients: Complete Statistical AnalysisIndependent statistical analysis of A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01014442).
- A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia: Complete Statistical AnalysisIndependent statistical analysis of A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia: primary endpoint…
- A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC): Complete Statistical AnalysisIndependent statistical analysis of A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low…
- A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin’s Lymphoma Grades 1, 2 or 3a: Complete Statistical AnalysisIndependent statistical analysis of A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a:…
- A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment: Complete Statistical AnalysisIndependent statistical analysis of A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment: primary endpoint results, effect estimate with confidence…
- A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).: Complete Statistical AnalysisIndependent statistical analysis of A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).: primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021): Complete Statistical AnalysisIndependent statistical analysis of A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021): primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68): Complete Statistical AnalysisIndependent statistical analysis of A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68): primary endpoint results, effect…
- A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045): Complete Statistical AnalysisIndependent statistical analysis of A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06): Complete Statistical AnalysisIndependent statistical analysis of A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06): primary endpoint results, effect estimate…
- A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC): primary…
- A Study of Pertuzumab in Participants With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Pertuzumab in Participants With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02491892).
- A Study of Pertuzumab in Participants With Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Pertuzumab in Participants With Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02480010).
- A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer’s Disease: Complete Statistical AnalysisIndependent statistical analysis of A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation: Complete Statistical AnalysisIndependent statistical analysis of A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection…
- A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02): Complete Statistical AnalysisIndependent statistical analysis of A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…